Advanced Genetics

About Advanced Genetics

Overview

Advanced Genetics is a peer-reviewed, open-access journal from Wiley, devoted to gene-related research across humans, animals, plants and microbes. Its ISSN is 2641-6573, recorded in the ISSN Portal as an online periodical that began with Volume 1, Issue 1 in December 2020, published by Wiley Periodicals Inc. from Hoboken, New Jersey, in the United States, in English. The Directory of Open Access Journals lists its publisher as Wiley, United States, gives its subject as genetics within biology, and records that it began publishing in open access in 2020. It belongs to Wiley's Advanced portfolio — the family of broad-scope, open-access Advanced journals — and Wiley's own journal description presents it as a broad-scope title with a recently expanded remit, a point developed in the scope section below.

That identity needs stating carefully, because the title is easy to confuse. Advanced Genetics — singular, Wiley, ISSN 2641-6573, launched in 2020 — is not Advances in Genetics, the long-running Elsevier book and serial tradition dating to the 1940s, and it is not a textbook with a similar name. Authors citing or submitting to the wrong title waste months; librarians and evaluators matching by title alone make the same error in reverse. The ISSN is the anchor: any record, metric or publisher claim for this journal should resolve to 2641-6573 and to Wiley.

This profile uses only the publisher's own description, the ISSN record and the DOAJ listing for its facts. It claims no Journal Impact Factor and no quartile, because no such figure was verified from the metric owners during preparation. Where the publisher describes an expanded scope in general terms, this profile paraphrases that description and explains what it means for authors, rather than presenting any topic the journal has not itself named.

Place in the Advanced portfolio and publishing history

Wiley launched Advanced Genetics at the end of 2020, into a genetics publishing landscape already crowded with society journals, clinical genetics titles and large commercial open-access journals. Its differentiator was portfolio and breadth. The Advanced portfolio is built around broad-scope, open-access journals that welcome work crossing traditional subject boundaries, with editorial handling by professional and academic editors under a shared identity. A genetics title in that portfolio signals to authors that interdisciplinary gene-related work — a genomics method applied to an agricultural problem, a bioinformatics tool tested on clinical data, an epigenomics study with ecological implications — has a home that will not reject it merely for sitting between established categories.

The ISSN record lists the journal's frequency as quarterly and its first issue as Volume 1, Issue 1 (December 2020); modern Wiley open-access journals in practice publish articles continuously as they are accepted, gathering them into volumes and issues, so authors should expect an article-first online workflow rather than waiting for a quarterly print cycle. The journal's presence in PubMed Central archiving, recorded in its DOAJ listing, reflects the biomedical weight of its content: a substantial share of genetics research is health-related, and deposit in PMC makes that share discoverable alongside the clinical literature and compliant with many funder public-access requirements.

Longevity claims should be kept proportionate. This is a young journal — launched in 2020 — building its reputation within a famous portfolio, not an old title with a century of back issues. That youth cuts both ways for authors. A young broad-scope journal can offer visibility through its portfolio, open-access reach and publisher marketing that a small independent title cannot; it cannot offer the decades-long track record that some tenure and promotion systems reward most heavily. Authors should weigh those considerations against their own institution's criteria, and should check the journal's current indexing in the specific databases their institution counts, on the date of submission.

Scope: the expanded remit explained

Wiley describes Advanced Genetics as a peer-reviewed, broad-scope, open-access journal dedicated to advancing gene-related research, with a recently expanded scope. In the publisher's description, it includes human, animal, plant and microbial genetics, genomics and epigenomics — and, importantly, topics that use genetic and omics technologies, bioinformatics, computational biology and artificial intelligence as toolboxes for discovery and innovation. That second clause is the expansion, and authors should understand what it does. It means a paper does not have to discover a gene to belong here; a paper that uses genetic or omics methods as its instrument — to answer a question in ecology, agriculture, medicine or another field — can also be in scope, provided the genetic component is central and expertly handled.

The publisher further frames the journal's welcome by purpose. It seeks fundamental, applied, clinical and translational research addressing critical scientific and societal challenges, naming the improvement of food security and sustainable agriculture; the conservation of biodiversity and ecosystem health; the improvement of human health and welfare; and the promotion of global One Health outcomes. One Health — the recognition that human, animal and environmental health are interdependent — is a useful lens for the whole scope: a study of antimicrobial resistance genes moving between livestock, soil and human gut microbiomes, for example, touches agriculture, ecology and medicine at once, and is exactly the kind of boundary-crossing work a broad-scope genetics journal exists to attract.

DOAJ's keyword summary for the journal gives the traditional core in compact form: genetics, genomics, epigenomics, genetic variants, copy number variations and genetic diseases. Read together, the two descriptions define a centre and a perimeter. The centre is gene science itself: variation, inheritance, regulation, mutation, genome structure and function, and the genetics of disease and traits. The perimeter is method-driven and challenge-driven work that uses that science as a toolbox. A manuscript at the perimeter should make its genetic core unmistakable in its title, abstract and methods; a manuscript whose genetics is incidental — a single marker used without expertise, in a paper really about something else — is likely to be judged out of scope or under-powered by the genetics reviewers a journal like this will consult.

Article formats are flexible by design. Wiley lists original research — covering novel findings, methods, software tools, case reports and data resources — alongside reviews and perspectives offering in-depth analysis and forward-looking insight, editorials and comments on broad scientific, ethical and policy questions, and meeting reports summarising key discussions, outcomes and future directions. That format list tells authors two things. First, resource and tool papers — a database, a pipeline, a well-documented dataset — are first-class contributions here, not filler, reflecting how central shared data and software have become to genetics. Second, ethical and policy commentary belongs in the journal's conversation: a field that edits genomes, tests embryos and sequences populations needs its ethics argued in its own literature, and this journal explicitly makes room for that argument.

Peer review, speed and editorial expectations

The DOAJ listing records anonymous peer review for this journal and states that it checks submissions for plagiarism; its headline expectation is an average of about fourteen weeks from submission to publication. Authors should read that figure as a listing average across the journal's workflow, not as a guaranteed timetable for any single paper: a manuscript sent for full review, revised substantially and re-reviewed will take longer than a paper accepted with minor changes, and either experience is normal. Wiley's submission system and author guidelines on the journal's Online Library hub are the controlling source for manuscript preparation — article structure, data availability statements, ethics approvals, sequence-data deposition and figure requirements — and they should be followed in their current form at submission.

Genetics manuscripts carry field-specific obligations that reviewers will enforce regardless of journal. Human genetics work needs ethics approval and consent arrangements that can be stated in the paper, and must handle the identifiability of genomic data honestly: a genome is identifying, and sharing plans must reflect that. Sequence and omics data are expected to be deposited in recognised public repositories with accession numbers supplied, so that findings can be checked and reused; a data availability statement that amounts to asking the corresponding author by email will not satisfy modern genetics standards. Variant and gene nomenclature should follow current human gene and variant conventions where applicable, statistical claims in genome-wide studies need proper correction for multiple testing, and computational methods need enough detail — versions, parameters, code location — for another group to reproduce the result. The journal's explicit welcome for software tools and data resources raises, rather than lowers, that reproducibility bar.

Animal, plant and microbial work carries parallel duties: clear organism and strain identification, ethical approval for animal experiments, and care with work that has ecological or biosecurity implications, such as genetic modification of wild populations or gain-of-function concerns in pathogens. Authors are not expected to resolve every policy debate in a methods section, but they are expected to show that the applicable approvals, permits and reporting standards for their organism and jurisdiction were addressed. A cover letter that states the advance plainly — what was unknown, what this study shows, and why it matters beyond its immediate system — helps editors route a broad-scope submission to the right reviewers.

Open access economics: licence, charges and waivers

Advanced Genetics is a fully open-access journal using a CC BY licence, with authors retaining unrestricted copyright and publishing rights, according to its DOAJ listing. Creative Commons Attribution is the most permissive standard licence: readers may share and adapt the work, including commercially, with proper credit. For authors, that maximises reuse — in teaching, in translation, in commercial research settings and in text-and-data mining — and it satisfies the open-access conditions of most major research funders, many of which specifically require CC BY or an equivalent. Articles are digitally archived in CLOCKSS, PubMed Central and Portico, per the same listing, giving the content multiple independent preservation routes beyond the publisher's own platform, and each article carries a DOI as its permanent identifier.

Open access at Wiley is funded by article processing charges. DOAJ lists this journal's charges as up to 2,960 US dollars, 2,060 pounds sterling or 2,660 euros, with a waiver policy for these charges. Three cautions apply to those numbers. First, they are the listing's up-to figures at the time of recording; the current charge is the one shown on the journal's Wiley pages when you submit, and it can differ by article type and over time. Second, many authors never pay the list price directly: Wiley has read-and-publish and open-access agreements with large numbers of universities and consortia under which an eligible corresponding author's charge is covered centrally, so the single most valuable pre-submission step is to check your institution's agreement status in Wiley's system. Third, the existence of a waiver policy is not a guarantee of a waiver; authors who would need one should enquire before submission, with their funding circumstances stated, rather than after acceptance.

The value judgement for an individual author is therefore concrete, not ideological. Price the actual route available to you — agreement-covered, waiver-supported or full charge — and set it against what the journal offers your paper: portfolio visibility, publisher production and marketing, PMC deposit for biomedical work, a CC BY licence that funders accept, and a broad-scope readership for interdisciplinary work. The same money judgement will come out differently for a well-funded clinical genomics group, a plant genetics team at an agreement-covered university, and an unfunded independent researcher, and the journal's waiver and agreement structures exist precisely because that is true.

Discoverability, indexing and responsible metric use

For a journal launched in 2020, the verifiable discoverability facts are these: it is listed in DOAJ with the archiving and metadata described above; its articles are archived in PubMed Central, which places its biomedical content inside the search environment clinicians and life scientists actually use; and it is published and distributed on Wiley Online Library, with a journal hub under its ISSN-based address. Beyond those facts, this profile deliberately asserts no database list and no metric. Scopus, Web of Science and other selective databases add and remove titles, and their coverage is the only authoritative evidence of their own lists; publisher and directory web pages routinely lag behind those decisions.

Responsible use of metrics follows from that caution. If your promotion case, thesis-by-publication rules or funder report requires a journal in a named database, or a quartile in a named category, search that database by ISSN 2641-6573 on the day you decide, and save the result. Do not rely on an impact figure quoted without a year and a source, and do not confuse this title's numbers with those of any similarly named title — the confusion risk identified at the start of this profile applies to metrics most of all. A journal's fit for your particular paper — its scope, its reviewers' expertise, its audience — is a better predictor of how the paper will be received and cited than a borrowed metric in any case, but where a formal requirement exists, verify it at the owner of the requirement, not here.

Readers evaluating a single Advanced Genetics article should apply the same evidence habits they would use anywhere in genetics: check whether the underlying data are deposited and linked, whether the article's claims match its sample sizes and corrections, whether a data or software paper's resource is actually live at its stated address, and whether ethical approvals and consent are stated for human or animal work. Open access makes that scrutiny possible for every reader, not only subscribers — one of the practical arguments for the model this journal has used since its first issue.

Is this the right journal for your manuscript?

Advanced Genetics is a strong candidate when your work is gene-centred but does not sit neatly inside one traditional subdiscipline: a cross-species genomics comparison, a clinical study whose mechanism is epigenomic, an agricultural trait study built on genome-wide data, a One Health microbiome genetics paper, or a bioinformatics or artificial-intelligence method whose value is demonstrated on real genetic data. It is also a rational candidate when your funder requires immediate CC BY open access, when PMC visibility matters for a biomedical audience, or when your contribution is a dataset or software resource that specialist journals in your area treat as secondary.

It is a weaker candidate when your paper is a narrow clinical report with minimal genetic content, a purely computational method with no substantive genetic application or validation, or a study whose data cannot be deposited and shared to the standard the field expects. It may also be the wrong choice, regardless of fit, if your institution requires a long-established title or a specific database listing that you cannot currently verify for this journal — that is an administrative fact about your situation, not a judgement on the journal's quality, and it should be faced before submission rather than after acceptance.

Prepare a submission the way its editors will read it: genetics first in the framing, societal or scientific challenge explicit, data deposition planned before you write the cover letter, ethics and consent statements drafted from your approvals rather than reconstructed afterwards, and nomenclature and statistics checked to current conventions. Broad-scope journals reward papers that explain themselves to intelligent readers outside their immediate niche; write the introduction for the plant geneticist as well as the clinician, or the clinician as well as the bioinformatician, and the journal's breadth becomes your paper's advantage instead of its obstacle.

Frequently asked questions

Is Advanced Genetics the same as Advances in Genetics? No. Advanced Genetics is the Wiley open-access journal launched in 2020 with ISSN 2641-6573. Advances in Genetics is a separate, much older Elsevier-associated serial tradition. Check the ISSN before citing or submitting.

What does it charge? Its DOAJ listing gives charges up to 2,960 USD, 2,060 GBP or 2,660 EUR, with a waiver policy. Many authors are covered by Wiley institutional agreements instead; check the current charge and your agreement eligibility on the journal's Wiley pages.

What licence applies? CC BY, with authors retaining unrestricted copyright and publishing rights, per its DOAJ listing.

How fast is it? DOAJ records an average expectation of about fourteen weeks from submission to publication. Individual manuscripts vary with review and revision.

Where is it archived? CLOCKSS, PubMed Central and Portico, per its DOAJ listing, with a DOI as the permanent article identifier.